Octocog alfa - Bayer

Drug Profile

Octocog alfa - Bayer

Alternative Names: Factor VIII - Bayer; Helixate; Kogenate; Recombinant factor VIII - Bayer

Latest Information Update: 19 Nov 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ipsen
  • Developer Bayer
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Haemophilia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 19 Nov 2002 Bayer's research collaboration with PolyMASC (Valentis) has expired and Bayer has decided not to enter into any further agreement
  • 19 Nov 2002 Bayer and PolyMASC have completed the feasibility study examining the use of PolyMASC's ProtoMASC technology for possible development of a chemically-modified factor VIII
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top